INTRODUCTION: Many studies have investigated the association of the dopamine type-2 receptor (DRD2) Taq1A polymorphism with tobacco use and cigarette smoking behaviors, but findings remain equivocal. There is a biological basis for considering that this association differs by sex, and differences in subpopulations might explain some of the contradictory evidence. METHODS: Our a priori hypothesis was that the association of the DRD2 Taq1A polymorphism with smoking behavior would be more prominent in females than males. We therefore investigated the strength of evidence for an association between the DRD2 Taq1A polymorphism and smoking behavior in a large sample of females and used meta-analytic techniques to synthesize existing published data and explore the role of sex in explaining any heterogeneity between studies. RESULTS: We did not observe any strong evidence of association between the DRD2 Taq1A polymorphism and smoking behavior, including smoking initiation, smoking persistence, and smoking rate, either in our female sample or in our meta-analysis of 29 studies, comprising 28 published studies and the data from the present study. Metaregression suggested an association between the proportion of male participants in a study and the individual study effect size, indicating a larger effect size with a greater proportion of male participants for smoking initiation and smoking persistence. This effect did not appear to be due to the inclusion of the data from the present study. DISCUSSION: Available evidence does not support an association between the DRD2 Taq1A polymorphism and smoking behavior. Contrary to our a priori hypothesis, we found evidence of a stronger association in males than in females.
INTRODUCTION: Many studies have investigated the association of the dopamine type-2 receptor (DRD2) Taq1A polymorphism with tobacco use and cigarette smoking behaviors, but findings remain equivocal. There is a biological basis for considering that this association differs by sex, and differences in subpopulations might explain some of the contradictory evidence. METHODS: Our a priori hypothesis was that the association of the DRD2 Taq1A polymorphism with smoking behavior would be more prominent in females than males. We therefore investigated the strength of evidence for an association between the DRD2 Taq1A polymorphism and smoking behavior in a large sample of females and used meta-analytic techniques to synthesize existing published data and explore the role of sex in explaining any heterogeneity between studies. RESULTS: We did not observe any strong evidence of association between the DRD2 Taq1A polymorphism and smoking behavior, including smoking initiation, smoking persistence, and smoking rate, either in our female sample or in our meta-analysis of 29 studies, comprising 28 published studies and the data from the present study. Metaregression suggested an association between the proportion of male participants in a study and the individual study effect size, indicating a larger effect size with a greater proportion of male participants for smoking initiation and smoking persistence. This effect did not appear to be due to the inclusion of the data from the present study. DISCUSSION: Available evidence does not support an association between the DRD2 Taq1A polymorphism and smoking behavior. Contrary to our a priori hypothesis, we found evidence of a stronger association in males than in females.
Authors: M R Spitz; H Shi; F Yang; K S Hudmon; H Jiang; R M Chamberlain; C I Amos; Y Wan; P Cinciripini; W K Hong; X Wu Journal: J Natl Cancer Inst Date: 1998-03-04 Impact factor: 13.506
Authors: E G Jönsson; M M Nöthen; F Grünhage; L Farde; Y Nakashima; P Propping; G C Sedvall Journal: Mol Psychiatry Date: 1999-05 Impact factor: 15.992
Authors: J D Robinson; C Y Lam; J A Minnix; D W Wetter; G E Tomlinson; J D Minna; T T-L Chen; P M Cinciripini Journal: Pharmacogenomics J Date: 2006-12-26 Impact factor: 3.550
Authors: G E Swan; A M Valdes; H Z Ring; T V Khroyan; L M Jack; C C Ton; S J Curry; T McAfee Journal: Pharmacogenomics J Date: 2005 Impact factor: 3.550
Authors: Elaine C Johnstone; Patricia L Yudkin; Kate Hey; Sarah J Roberts; Sarah J Welch; Michael F Murphy; Siân E Griffiths; Robert T Walton Journal: Pharmacogenetics Date: 2004-02
Authors: Huaiyu Mi; Paul D Thomas; Huijun Z Ring; Ruhong Jiang; Katrin Sangkuhl; Teri E Klein; Russ B Altman Journal: Pharmacogenet Genomics Date: 2011-06 Impact factor: 2.089
Authors: Sean P David; Elaine C Johnstone; Michael Churchman; Paul Aveyard; Michael F G Murphy; Marcus R Munafò Journal: Nicotine Tob Res Date: 2011-01-25 Impact factor: 4.244
Authors: Carlos Blanco; María García-Anaya; Melanie Wall; José Carlos Pérez de Los Cobos; Ewelina Swierad; Shuai Wang; Nancy M Petry Journal: Drug Alcohol Depend Date: 2015-02-25 Impact factor: 4.492
Authors: Diana R Samek; Jennifer Bailey; Karl G Hill; Sylia Wilson; Susanne Lee; Margaret A Keyes; Marina Epstein; Andrew Smolen; Michael Miller; Ken C Winters; J David Hawkins; Richard F Catalano; William G Iacono; Matt McGue Journal: Behav Genet Date: 2016-07-21 Impact factor: 2.805
Authors: James MacKillop; Joshua C Gray; L Cinnamon Bidwell; Warren K Bickel; Christine E Sheffer; John E McGeary Journal: Psychopharmacology (Berl) Date: 2015-07-29 Impact factor: 4.530